Rubric Capital Management LP bought a new stake in shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) during the second quarter, Holdings Channel reports. The firm bought 577,900 shares of the biopharmaceutical company’s stock, valued at approximately $6,068,000.

Several other hedge funds have also modified their holdings of SCMP. State Street Corp raised its position in Sucampo Pharmaceuticals by 32.9% in the fourth quarter. State Street Corp now owns 581,835 shares of the biopharmaceutical company’s stock worth $7,882,000 after buying an additional 143,906 shares during the period. Bank of Montreal Can raised its position in Sucampo Pharmaceuticals by 22.9% in the first quarter. Bank of Montreal Can now owns 24,775 shares of the biopharmaceutical company’s stock worth $272,000 after buying an additional 4,615 shares during the period. Capstone Asset Management Co. purchased a new position in Sucampo Pharmaceuticals during the first quarter worth approximately $133,000. Louisiana State Employees Retirement System purchased a new position in Sucampo Pharmaceuticals during the first quarter worth approximately $111,000. Finally, Palisade Capital Management LLC NJ raised its position in Sucampo Pharmaceuticals by 1.7% in the first quarter. Palisade Capital Management LLC NJ now owns 30,000 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 500 shares during the period. Institutional investors and hedge funds own 58.20% of the company’s stock.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) opened at 10.25 on Friday. The firm’s market capitalization is $474.83 million. The firm has a 50-day moving average of $10.71 and a 200-day moving average of $10.68. Sucampo Pharmaceuticals, Inc. has a 52-week low of $9.30 and a 52-week high of $17.55.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.06. The firm had revenue of $59.90 million for the quarter, compared to the consensus estimate of $56.44 million. Sucampo Pharmaceuticals had a negative net margin of 61.99% and a positive return on equity of 56.58%. The business’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.24 earnings per share. On average, equities research analysts forecast that Sucampo Pharmaceuticals, Inc. will post $1.02 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.dailypolitical.com/2017/08/13/rubric-capital-management-lp-takes-position-in-sucampo-pharmaceuticals-inc-scmp.html.

SCMP has been the topic of a number of recent analyst reports. Jefferies Group LLC set a $13.00 price target on shares of Sucampo Pharmaceuticals and gave the company a “hold” rating in a research report on Thursday, April 20th. ValuEngine lowered shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Zacks Investment Research upgraded shares of Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 4th. Maxim Group set a $23.00 price target on shares of Sucampo Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 2nd. Finally, TheStreet lowered shares of Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research report on Wednesday, August 2nd. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $17.63.

In other news, insider Jones W. Bryan acquired 4,700 shares of Sucampo Pharmaceuticals stock in a transaction on Friday, August 4th. The shares were purchased at an average cost of $10.60 per share, for a total transaction of $49,820.00. Following the completion of the purchase, the insider now directly owns 4,700 shares of the company’s stock, valued at approximately $49,820. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 4.13% of the company’s stock.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Want to see what other hedge funds are holding SCMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).

Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.